Evidence map›Paper›PMID 37066181›Full record

ArticlebioRxiv : the preprint server for biology2023

Peptidoglycan from

Joshua S Mytych, Zijian Pan, Charmaine Lopez-Davis, Nancy Redinger, Christina Lawrence, Jadith Ziegler, Narcis I Popescu, Judith A James, A Darise Farris

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Joshua S MytychArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13 Street, Oklahoma City, OK 73104, USA.
Zijian PanArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13 Street, Oklahoma City, OK 73104, USA.
Charmaine Lopez-DavisArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13 Street, Oklahoma City, OK 73104, USA.
Nancy RedingerArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13 Street, Oklahoma City, OK 73104, USA.
Christina LawrenceArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13 Street, Oklahoma City, OK 73104, USA.
Jadith ZieglerArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13 Street, Oklahoma City, OK 73104, USA.
Narcis I PopescuArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13 Street, Oklahoma City, OK 73104, USA.
Judith A JamesArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13 Street, Oklahoma City, OK 73104, USA.
A Darise FarrisArthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, 825 NE 13 Street, Oklahoma City, OK 73104, USA.
Oklahoma Medical Research Foundation · US

Funding

Tracking and Evaluation CoreU54GM104938 · NIGMS · UNIVERSITY OF OKLAHOMA HLTH SCIENCES CTR · PI Janis E Campbell · 2013 to 2026
$68.2M
Translation of immunologic technologies from basic research into pre-clinical nonU19AI062629 · NIAID · OKLAHOMA MEDICAL RESEARCH FOUNDATION · PI COGGESHALL, KENNETH MARK · 2004 to 2023
$56.2M
NIAID NIH HHS U19 AI062629NIGMS NIH HHS U54 GM104938
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ADAM17Bacillus anthracisefferocytosisMerTKpeptidoglycan

Identifiers

PMID37066181
PMCPMC10103956
OpenAlexW4362512641

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.